Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report diagnosed prevalence of vitiligo for each country, as well…
Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report diagnosed prevalence of vitiligo for each country, as well…
Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report diagnosed prevalence of vitiligo for each country, as well…
Clarivate Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report diagnosed prevalence of vitiligo for each country, as well…